There are no drugs available to cure Alzheimer’s disease. The available treatment consists of two aspects, one is to increase acetylcholine transmitters in the central nervous system to improve cognitive function, and the other is to protect neural tissue through antioxidants. Clinically proven effective drugs to increase the transmitter are acetylcholinesterase inhibitors, which, by inhibiting the enzyme, increase acetylcholine levels in the central nervous system. Treatment improves cognitive function as well as psychobehavioral symptoms in AD patients, but does not alter the course of AD. There are three medications in this class, namely Amrin, Galantamine and Elsenon. The main side effects are gastrointestinal reactions such as nausea, vomiting, diarrhea, anorexia and weight loss, but they are generally well tolerated. Since they belong to the same class of drugs, it is generally believed that the difference between the three is the degree of intestinal reactions, the dose and the different dosing processes. Memantine is an NMDA receptor agonist, which is also approved for AD. Its pharmacological mechanism is not fully understood and may be related to its non-competitive agonism of NMDA receptors, thus protecting cholinergic neurons from excitatory amino acid toxicity. It can be used in patients with intermediate to late stage AD. It has fewer side effects and can be used in combination with other cholinesterase inhibitors. Side effects include hallucinations, confusion, dizziness, and headache. Experiments have shown that free radicals play a role in the progression of AD, therefore, the use of antioxidants such as vitamin E and Slegiline has been thought to treat AD, but reports of clinical outcomes are conflicting, and high doses made with vitamin E may increase mortality in patients. Other drugs such as anti-inflammatory drugs, hormones, estrogens, and statins have also been used to treat AD, but their efficacy has not been proven. Herbal preparations include Kinnado and Haberin. Kinnado has been used in the treatment of AD in conflicting reports and currently tends to be ineffective. Haberin, a stigmasterine alkaloid isolated from the Chinese herb millipedium, is a natural inhibitor of acetylcholinesterase, and although it has been used clinically in China, its efficacy in the treatment of AD needs further confirmation. Another aspect of AD treatment is to mainly target the psycho-behavioral symptoms associated with dementia, such as agitation, depression, anxiety, psychotic symptoms, and insomnia. Agitation and psychiatric abnormalities are symptoms of advanced AD, but advanced AD is often combined with electrically mediated disturbances, infections, and pain that cause delirium, and thus these causes need to be ruled out. In the absence of these abnormalities, psychiatric drugs, antiepileptic drugs, methotrexate, or other anxiolytic drugs can be tried to treat agitation. Antipsychotics should be avoided because they have some serious side effects such as extrapyramidal symptoms, falls, and delayed-onset dyskinesia. Depression can be treated with SSRIs or with NE and SSRI antidepressants such as venlafaxine. anxiety in AD patients generally does not require special treatment, insomnia symptoms are treated with non-pharmacological methods as much as possible, and benzodiazepines may aggravate the impairment of cognitive function. Meprobamate can be used to treat insomnia in patients.